AGIO Capital & Business Solutions supported Complix in signing a global drug discovery and development agreement against two immuno-oncology intracellular targets, with Nasdaq listed I-Mab.
Complix, a Belgian biopharmaceutical company developing a pipeline of transformative Alphabody therapeutics announces that it has signed a significant drug discovery deal with I-Mab (Nasdaq: IMAB), an innovation-driven clinical stage biopharmaceutical company committed to novel & differentiated biologics in immuno-oncology.
Under the terms of the agreement, Complix will receive upfront fees and research funding, as well as milestone and royalty payments to deliver Cell Penetrating Alphabodies (CPABs) against two immuno-oncology intracellular targets, using its proprietary Alphabody platform. The resulting CPABs will undergo clinical development that will be jointly managed by both companies. I-Mab will have an exclusive license to commercialize the CPABs in Greater China, while Complix retains joint development and commercialization rights in the rest of the world.
CPABs are a revolutionary class of small proteins engineered to bind to a variety of antigens. Data available show that CPABs have the potential to address a wide range of disease targets, particularly intracellular targets that are difficult for current therapies to reach.
In addition to crossing cellular membranes, Alphabodies have the potential to cross the blood brain barrier to address CNS diseases and to be delivered orally given their ability to cross the gut wall.
How Agio Capital & Business helped
AGIO Capital & Business Solutions successfully supported Complix in identifying key strategic partners in China and providing advisory services during the strategic partnering discussions with I-Mab.
Click here for the full press release.
